| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
No specific biological target. L-Serine-1-¹³C is a stable isotope-labeled amino acid used as a metabolic tracer. It is incorporated into metabolic pathways involving serine, including one-carbon metabolism, glycine synthesis, and phospholipid biosynthesis.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
L-Serine-1-¹³C is used as a tracer to study serine metabolism. The ¹³C label allows for tracking of the carboxyl carbon of serine through metabolic pathways. No direct pharmacological activity or receptor binding has been reported as the compound is a stable isotope-labeled amino acid. |
| ln Vivo |
L-Serine-1-¹³C is used in in vivo metabolic tracing studies to track serine flux and incorporation into downstream metabolites. It has been used in animal models to study serine metabolism in cancer, neurodegeneration, and metabolic disorders. Detailed pharmacodynamic effects are not applicable as the compound is a tracer.
|
| Enzyme Assay |
Not applicable. L-Serine-1-¹³C is a stable isotope-labeled amino acid and is not used in enzyme/receptor binding assays as a pharmacological agent. It is used as a tracer in metabolic flux analysis.
|
| Cell Assay |
Metabolic tracing assay: Cells or tissues are cultured with L-Serine-1-¹³C at varying concentrations for specified time periods. Metabolites are extracted and analyzed by LC-MS/MS or NMR. The incorporation of ¹³C label into downstream metabolites (e.g., glycine, one-carbon intermediates, phospholipids) is quantified to determine metabolic flux.
|
| Animal Protocol |
Metabolic tracing in animal models: Animals are administered L-Serine-1-¹³C via oral gavage, intraperitoneal injection, or intravenous infusion. Blood, tissues, and organs are collected at various time points. Metabolites are extracted and analyzed by LC-MS/MS or NMR to track ¹³C incorporation into serine metabolism pathways.
|
| ADME/Pharmacokinetics |
L-Serine-1-¹³C has a molecular weight of 106.09 g/mol and molecular formula ¹³CC₂H₇NO₃. CAS number is 81201-84-5. The compound is a stable isotope-labeled amino acid with ≥98% isotopic enrichment. It is stored as a powder at room temperature.
|
| Toxicity/Toxicokinetics |
No toxicity data has been published as L-Serine-1-¹³C is a stable isotope-labeled amino acid, not a therapeutic compound. It is for research use only. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
L-Serine-1-¹³C is a stable isotope-labeled form of L-serine where the carboxyl carbon is replaced with ¹³C. It is used as a metabolic tracer to study serine metabolism, one-carbon metabolism, glycine synthesis, and phospholipid biosynthesis. The compound is a research reagent and not a therapeutic drug. No clinical trials or approved上市 status have been reported.
|
| Molecular Formula |
C213CH7NO3
|
|---|---|
| Molecular Weight |
106.08
|
| Exact Mass |
106.046
|
| CAS # |
81201-84-5
|
| Related CAS # |
L-Serine;56-45-1
|
| PubChem CID |
134039
|
| Appearance |
White to off-white solid powder
|
| Density |
1.415g/cm3
|
| Melting Point |
222ºC (dec.)(lit.)
|
| Index of Refraction |
1.519
|
| LogP |
-3.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
7
|
| Complexity |
72.6
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@@H]([13C](=O)O)N)O
|
| InChi Key |
MTCFGRXMJLQNBG-NSQKCYGPSA-N
|
| InChi Code |
InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1/i3+1
|
| Chemical Name |
(2S)-2-amino-3-hydroxy(113C)propanoic acid
|
| Synonyms |
L-(1-13C)Serine; L-(l-13C)Serine; L-Serine-1-13C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~2356.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.4268 mL | 47.1342 mL | 94.2685 mL | |
| 5 mM | 1.8854 mL | 9.4268 mL | 18.8537 mL | |
| 10 mM | 0.9427 mL | 4.7134 mL | 9.4268 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
